Elanco Animal Health Inc (ELAN): Total Liabilities
$6.81B
As of 2025-12-31
$6.97B
As of 2026-06-30
-6.0%
3-year compound annual growth
-5.9%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.81B | +4.5% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $6.52B | -19.9% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $8.14B | -0.8% | 2025-02-25, Balance as of period end |
| 2022-12-31 | $8.20B | -8.6% | 2024-02-26, Balance as of period end |
| 2021-12-31 | $8.97B | -2.7% | 2023-03-01, Balance as of period end |
| 2020-12-31 | $9.22B | +168.0% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $3.44B | -8.5% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $3.76B | +224.1% | 2020-02-28, Balance as of period end |
| 2017-12-31 | $1.16B | n/a | 2019-02-20, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $6.81B | +4.5% |
| Perrigo Co PLC (PRGO) | 2025-12-31 | $5.60B | +5.1% |
| BeOne Medicines Ltd. (ONC) | 2025-12-31 | $3.83B | +47.9% |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $4.18B | +0.1% |
| Organon & Co. (OGN) | 2025-12-31 | $12.12B | -4.1% |
| BioMarin Pharmaceutical Inc (BMRN) | 2025-12-31 | $1.51B | +13.2% |
| United Therapeutics Corp (UTHR) | 2025-12-31 | $783.80M | -14.8% |
| Royalty Pharma plc (RPRX) | 2025-12-31 | $9.91B | +25.7% |
| Zoetis Inc. (ZTS) | 2025-12-31 | $12.14B | +28.2% |
Compare ELAN, PRGO, ONC, ALNY side by side · Screen every company in Pharmaceutical Preparations ↗